How many insider trades does FilingIQ track for NERV?

FilingIQ tracks 171 Form 4 insider transactions for NERV (Minerva Neurosciences, Inc.), covering filings from Jan 22, 2015 onwards. 2 of those were filed in the last 90 days.

Are NERV insiders net buyers or net sellers?

Across the full Form 4 history for NERV, 29 transactions (17%) were open-market purchases and 54 (32%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does NERV insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is NERV in?

Minerva Neurosciences, Inc. (NERV) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $273.93M.

NERV insider trading

NasdaqCM Healthcare

Minerva Neurosciences, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

171

Last 90 days

Buys / sells

17% / 32%

Market cap

$273.93M

About Minerva Neurosciences, Inc.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Company website: www.minervaneurosciences.com

NERV insider activity at a glance

FilingIQ has scored 171 insider transactions for NERV since Jan 22, 2015. The most recent filing in our index is dated Apr 21, 2026.

Across the full history, 29 open-market purchases and 54 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on NERV insider trades is 55.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live NERV trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for NERV?: FilingIQ tracks 171 Form 4 insider transactions for NERV (Minerva Neurosciences, Inc.), covering filings from Jan 22, 2015 onwards. 2 of those were filed in the last 90 days.
Are NERV insiders net buyers or net sellers?: Across the full Form 4 history for NERV, 29 transactions (17%) were open-market purchases and 54 (32%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does NERV insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is NERV in?: Minerva Neurosciences, Inc. (NERV) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $273.93M.

Methodology & sources

Every NERV insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.